Skip to content

SankoreAfrican research intelligence

Countries
Institutions
Fields
Rankings
Compare

Search institutions, scholars, countries and publications

Sankore

Named after the University of Sankore in Timbuktu — one of the world’s oldest centres of learning. Every figure here is computed from work-level records in our own graph, never copied from a source’s summary count.

Built from

OpenAlex — works, authorships, subject classification
ROR — institutional identity
ORCID — researcher identity
Crossref — publisher confirmation

Browse

Countries
Institutions
Fields
Rankings
What we cover

Coverage is partial and says so. A country appears with its research output only once its works have been swept; until then the portal shows whatever the graph happens to hold for it and labels it as exactly that.

Opokua Ofori-Anyinam · Sankore

Opokua Ofori-Anyinam

ORCID, self-asserted

ORCID 0000-0001-8099-6837

This profile carries an ORCID the researcher published on their own record — the strongest evidence available short of a human confirming it.

Publications

4

Citations

118

h-index

4

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

3

Publications

3 works in the graph, newest first.

Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial
2024The Lancet Infectious DiseasesJournalOpen access17 citations10.1016/s1473-3099(24)00179-8
Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine
2024The Journal of Infectious DiseasesJournalOpen accessSenior authorCorresponding4 citations10.1093/infdis/jiae075
Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
2022The Lancet Infectious DiseasesJournalOpen access75 citations10.1016/s1473-3099(22)00273-0